Journal
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH
Volume 11, Issue 1, Pages 33-47Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/152581602753448522
Keywords
-
Funding
- NCI NIH HHS [CA-62242, CA-85818] Funding Source: Medline
Ask authors/readers for more resources
Tumor angiogenesis is currently not only a concept but has also become a rationale for the therapeutic use of both old and new drugs that might affect new blood vessel formation. There is growing evidence that angiogenesis is as important in hematologic malignancies as it is in solid tumors. Both myeloid and lymphoid disorders may be accompanied by a prognostically detrimental increase in bone marrow microvessel density. In this review, we summarize the current literature as well as our own studies regarding bone marrow angiogenesis and the use of anti-angiogenic treatment in hematologic disorders. Background information on pathogenesis and laboratory methods of quantifying bone marrow angiogenesis is also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available